Biopharmaceutical company GSK PLC (LSE: GSK) (NYSE: GSK) announced on Wednesday that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for gepotidacin, an investigational oral antibiotic aimed at treating uncomplicated urinary tract infections (uUTIs) in female adults and adolescents. The application has been granted Priority Review status, with a Prescription Drug User Fee Act (PDUFA) action date set for 26 March 2025.
Gepotidacin has the potential to be the first new class of oral antibiotics for uUTIs in over 20 years, addressing an urgent need as drug-resistant bacteria increasingly contribute to treatment failures. The NDA is backed by positive outcomes from pivotal phase III trials, EAGLE-2 and EAGLE-3, where gepotidacin showed non-inferiority and, in some instances, superiority to nitrofurantoin, the current standard treatment.
The trials involved over 3,100 female participants, with gepotidacin achieving therapeutic success rates of 50.6% to 58.5% compared to 43.6% for nitrofurantoin. The safety profile was consistent with prior studies, predominantly reporting gastrointestinal adverse events.
Gepotidacin represents a significant advancement in GSK's infectious disease portfolio, which is supported by federal funding from the US Department of Health and Human Services. GSK continues to develop innovative solutions to combat antimicrobial resistance, enhancing its diverse pipeline of medicines and vaccines.
Sanofi commits USD18m to boost diversity in clinical studies
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
Saniona reaches milestone in Boehringer Ingelheim partnership
Lipella granted patent for innovative drug delivery technology
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
PharmAbcine's PMC-403 Phase one clinical trial single ascending dose cohort receives safety approval
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
Lundbeck agrees to acquire Longboard Pharmaceuticals to enhance neuroscience pipeline